▎Edited by the WuXi AppTec content teamAccording to incomplete statistics from Innovation Radar, last week (February 10 to February 16), the global health sectorA total of 35 financing events were disclosed, with a total amount exceeding 6.9 billion yuan.。In terms of amount, there were 11 financings of 100 million yuan and above.According to the disclosed financing rounds, there were 15 early-stage financings (before Series B) and 15 mid-to-late stage financings (Series B and later). A total of 11 companies in the biopharmaceutical field received financing, involving drug types including innovative small molecules, bispecific antibodies, stem cell therapies, etc.
Abcuro Completes $200 Million Series C Financing
Keywords: Immunomodulatory Antibody TherapyLatest Financing:$200 Million Series CThis round of investment institutions: Abrdn, Eurofarma Ventures, Foresite Capital, Mass General Brigham Ventures, etc.News on February 13: Abcuro announced the completion of a $200 million Series C financing. The proceeds from this Series C round will be used to completePivotal Phase 2/3 MUSCLE Clinical TrialThe trial aims to evaluate the efficacy and safety of Abcuro's potential "first-in-class" killer cell lectin-like receptor G1 (KLRG1)-targeted monoclonal antibody ulviprubart (ABC008) for the treatment of inclusion body myositis (IBM). If the MUSCLE clinical trial yields positive results, Abcuro plans to submit a Biologics License Application (BLA) and will allocate part of the funds to support preparations for commercial launch. Both the U.S. FDA and the European Medicines Agency (EMA) have granted ulviprubart orphan drug designation for the treatment of IBM.Aardvark Therapeutics Goes Public on Nasdaq
Keyword: Small Molecule Drugs
Latest Financing:Approximately $94.2 Million IPO2On the 12th, Aardvark Therapeutics announced the pricing of its initial public offering of common stock. Aardvark is a clinical-stage biopharmaceutical company focused on developing novel small-molecule therapies that activate innate homeostatic pathways to treat metabolic diseases. Aardvark’s lead candidate product, ARD-101, targets bitter taste receptors (TAS2R) expressed in the intestinal lumen, inducing the secretion of endogenous signaling molecules, including the satiety hormone cholecystokinin (CCK), which in turn activates gut-brain signaling to suppress hunger. This potential “First-in-class” oral investigational drugDemonstrated clinical activity and good tolerability in Phase 2 trials, and has entered phase 3 clinical development for hyperphagia associated with Prader-Willi syndrome, and has been granted orphan drug designation.Newleos Therapeutics Completes $93.5 Million Financing
Keywords: Central Nervous System Disease Drugs
Latest Financing:$93.5 Million Series ANews on February 13: Newleos Therapeutics announced the completion of a $93.5 million Series A financing round. Currently, the company’s projects cover a variety of oral small molecules targeting generalized anxiety, social anxiety, substance use disorders, and cognitive impairments.New Mechanism. Newleos Therapeutics' leading clinical project NTX-1955 (RO7308480) is a potential "first-in-class" GABAA-γ1 Selective Positive Allosteric Modulator (PAM) for the Treatment of Anxiety. NTX-1955 Specifically Modulates GABAergic Transmission in Anxiety-related Brain Circuits by Targeting GABA A Receptors Containing the γ1 (γ-1) Subunit, Which Are Highly Abundant in the Amygdala.NTX-1955 has entered Phase 1 trial, including single-dose and multi-dose escalation studies, drug interaction and receptor occupancy studies, demonstrating its safety, good tolerability, strong brain penetration, and selectivity for GABAA-γ1. Newleos Therapeutics plans to study NTX-1955 for the treatment of generalized anxiety disorder in proof-of-concept clinical trials.
Bambusa Therapeutics Completes $90 Million Series A Financing
Keywords: Bispecific Antibody DrugsLatest Financing:$90 Million Series AThis round of investment institutions: ADAR1 Capital Management, Invus, Janus Henderson Investors, RA Capital Management, Redmile Group
News on February 14: Bambusa Therapeutics announced the completion of a $90 million Series A financing round, which will be used to supportPhase 1 Clinical Trial of the Pilot Project, and further advance the development of its pipeline. Bambusa has established a robust pipeline of long-acting bispecific antibodies, where BBT001 targets dermatological conditions, and BBT002 can be applied to respiratory, dermatological, and gastrointestinal indications. Bambusa's other development candidates, BBT003 and BB004, also show therapeutic potential for inflammatory bowel disease and rheumatological indications.
Gempharmatech Completes Tens of Millions of Yuan in Series B+ Financing
Keywords:Stem Cell Therapy Drugs
MostNew Financing: Tens of Millions of Yuan in B+ Round
This round of investment institutions: Fir Creek CapitalNews on February 10: Jimeirisheng recently completed a B+ round of financing worth tens of millions of yuan, which will be used for related purposes under the company.Clinical Development and Regulatory Submission of Stem Cell ProductsGMR Bio was established in 2015, focusing on the field of regenerative medicine for human organs using stem cells. By developing innovative cell and gene therapy products, the company aims to repair, regenerate, and enhance human tissues and organs. REGEND001, an innovative pulmonary regenerative medicine product independently developed by the company, has successively completed two Phase II clinical studies, targeting chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF), respectively.Readers, please star⭐Chuangjianhui to receive updates第一时间.
Disclaimer: The content team of WuXi AppTec focuses on introducing the research progress in global biopharmaceuticals and health. This article is for information exchange only, and the views expressed in the article do not represent the position of WuXi AppTec, nor does it mean that WuXi AppTec supports or opposes the views in the article. This article is not a recommendation for treatment plans. If you need guidance on treatment options, please visit a regular hospital.
Copyright Statement: This article was compiled and edited by the content team of WuXi AppTec based on publicly available information. Individuals are welcome to share it on their social media platforms, but unauthorized republication or reproduction by media or institutions in any form to other platforms is strictly prohibited. For authorization to repost, please contact"Chuang Jian Hui"Contact us by leaving a message on the WeChat Official Account.
More Data Content RecommendationsClick "InSee", Sharing the Latest Health Trends from Chuangjian Hui
